NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

囊狀纖維化症:資訊分析報告(2010年∼2021年)

Cystic Fibrosis - Deals Analytics Report, 2010 to 2021

出版商 GervanoRA Data Services LLP 商品編碼 1024237
出版日期 內容資訊 英文 60 Pages
商品交期: 3-5個工作天內
價格
囊狀纖維化症:資訊分析報告(2010年∼2021年) Cystic Fibrosis - Deals Analytics Report, 2010 to 2021
出版日期: 2021年08月11日內容資訊: 英文 60 Pages
簡介

本報告以囊狀纖維化症為焦點,除了分析囊狀纖維化症的全球治療情形以外,更彙整各市場區隔的資本交易趨勢,主要企業分析,資本交易相關案例研究等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 交易分析

  • 協定
  • 聯盟
  • 合併·收購
  • 資金籌措
  • 授權契約
  • 聯盟

第4章 交易額及地區

第5章 主要企業分析

第6章 年度頻率分析

第7章 案例研究:主要5件

第8章 簡稱

目錄
Product Code: GERPD001

GervanoRA's 'Cystic Fibrosis Deals Activity Report, 2010-2021' has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.

GervanoRA has analyzed more than 90 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.

The report through its meticulous analysis on global therapeutic landscape of Cystic Fibrosis deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.

For a proper understanding, GervanoRA has segmented the report into sections based on:

  • Analytics based on deal type,
  • Analytics based on deal by value,
  • Analytics based on geography
  • Analytics based on deal maker
  • Year-by-year analytics

The report also includes case studies provided for the deals that were prominent and unique among all the deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

3. ANALYTICS BY DEAL TYPE

  • 3.1. CYSTIC FIBROSIS AGREEMENTS
  • 3.2. CYSTIC FIBROSIS COLLABORATIONS
  • 3.3. CYSTIC FIBROSIS MERGERS & ACQUISITIONS
  • 3.4. CYSTIC FIBROSIS FINANCING- GRANT AND FUNDING DEALS
  • 3.5. CYSTIC FIBROSIS LICENSING DEALS
  • 3.6. CYSTIC FIBROSIS ALLIANCE DEAL

4. ANALYTICS BY DEAL VALUE AND GEOGRAPHY

5. ANALYTICS BY ACTIVE PLAYERS

6. ANALYTICS BY ANNUAL FREQUENCY

7. CASE STUDIES- TOP FIVE PROMINENT DEALS

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: MAJOR AGREEMENTS IN THE CYSTIC FIBROSIS AREA
  • TABLE 02: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 03: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE CYSTIC FIBROSIS AREA
  • TABLE 05: MAJOR LICENSING DEALS IN THE CYSTIC FIBROSIS AREA
  • TABLE 06: TOP 10 MAJOR DEALS IN THE CYSTIC FIBROSIS AREA RANKED BY DEAL AMOUNT

LIST OF FIGURES

  • FIGURE 01: CYSTIC FIBROSIS DEALS, BY DEAL TYPE
  • FIGURE 02: CYSTIC FIBROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 03: CYSTIC FIBROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT
  • FIGURE 04: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN CF AREA
  • FIGURE 05: NUMBER OF CYSTIC FIBROSIS DEALS, YEAR BY YEAR
  • FIGURE 06: INCREASING AGREEMENT DEALS